Exo, a health information and medical devices company, has purchased Medo, a developer of artificial intelligence technology.
The deal allows Exo to make ultrasound imaging more accessible to a range of caregivers.
“This acquisition is about bringing unprecedented ease of use to ultrasound imaging — allowing caregivers to obtain and interpret ultrasound images,” said Sandeep Akkaraju, CEO of Exo. “Medo has built a robust AI pipeline to go from acquiring medical images to FDA-cleared software. We are excited about joining forces with an innovative team that shares our vision of taking medical imaging everywhere.”